X-37, LLC, an artificial intelligence-enabled drug discovery company, announced today that David Gluckman, M.D., has joined the company’s Board of Directors. Dr. Gluckman is Vice Chairman of Investment Banking and Global Head of Lazard’s Healthcare Group. He has been with Lazard since 1998, providing strategic and financial advice to senior executives and boards of directors at leading healthcare companies globally.
“We welcome Dr. Gluckman to X-37’s Board of Directors and look forward to benefitting from his experience and expertise in corporate strategy and finance as we advance our discovery and development programs against a variety of pharmaceutical targets,” said David Collier, M.D., CEO and cofounder of X-37. “Dr. Gluckman’s network and experience will be very valuable to X-37 as we seek to capitalize on these developments through partnerships with, and acquisitions by, major pharmaceutical companies.”
X-37 identifies high-value drug targets, generates novel drug leads against these targets using Atomwise’s AI platform for structure-based drug design, and develops each of these drug programs to a medically-relevant inflection point, where it can be acquired by or partnered with a major pharmaceutical company to be brought to market. X-37 makes use of an LLC structure permitting each drug development program to be housed in a separate virtual company under the parent LLC. This structure allows X-37 to divest individual drug development programs, while maintaining the parent company and team.
“X-37’s flexible business model allows these successful drug hunters to do what they do best, discover and develop novel drug candidates for important diseases,” said Dr. Gluckman. “I look forward to providing strategic guidance to the X-37 leadership team to help them capitalize their multiple therapeutic opportunities.”
Dr. Gluckman is a member of the Advisory Board of the Vagelos Program in Life Sciences and Management, jointly administered by the College of Arts and Sciences and the Wharton School at the University of Pennsylvania. He is a member of the Board of Trustees of the Hackley School. He is a member of the Leadership Council of AmeriCares and is a Lazard representative in The Council of Foreign Relations, Corporate Leader Program. Prior to joining Lazard, Dr. Gluckman was a practicing physician in Toronto, Canada. Dr. Gluckman is a licentiate of the Medical Council of Canada and a member of the College of Physicians and Surgeons of Ontario.
X-37 is a pharmaceutical discovery and development company, which uses advanced artificial intelligence technology from Atomwise, Inc., to screen vast libraries of chemical compounds against high value pharmaceutical targets. X-37 develops these novel drug candidates under an innovative LLC structure which allows the sale or partnership of individual development programs in a simple and efficient manner. The team at X-37 possesses deep expertise in pharmaceutical development and the selection of pharmaceutical targets of high importance. For more information, please visit www.x37.ai.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201030005155/en/
Jessica Yingling, Ph.D., Little Dog Communications Inc., +1 858-344-8091, [email protected]
David S. Wilkes, MD, dean of the University of Virginia School of Medicine, has been elected to the National Academy of Medicine, one of the highest honors in the fields of health and medicine.
Wilkes was among 100 new members elected this week to the National Academy, which has more than 2,000 members chosen by current members for their contributions to the advancement of the medical sciences, healthcare and public health.
“I am honored to be joining the National Academy of Medicine,” Wilkes said. “I am so appreciative of this recognition from national leaders in healthcare and scientific research.”
A Leader in Research and Diversifying Medicine
Wilkes has served as dean and James Carroll Flippin Professor of Medical Sciences at the UVA School of Medicine since September 2015. Under his leadership, the School of Medicine has steadily increased its research funding, earning a UVA-record $146.3 million in funding from the National Institutes of Health in fiscal year 2019.
Along with helping to bolster UVA’s research enterprise, Wilkes has made significant contributions of his own to the field of biomedical research. He has co-authored more than 100 research papers, holds six U.S. patents and co-founded ImmuneWorks Inc., which researched and developed treatments for immune-mediated lung diseases including idiopathic pulmonary fibrosis and lung transplant rejection.
He has also worked to diversify the ranks of healthcare faculty members, serving since 2013 as national director of the Harold Amos Medical Faculty Development Program for the Robert Wood Johnson Foundation. The program seeks to increase the number of medical, dental and nursing faculty from historically disadvantaged backgrounds.
“David has had a tremendous career as a researcher, a leader in academic medicine and as an educator and mentor to countless physician scientists,” said K. Craig Kent, MD, UVA’s executive vice president for health affairs. “He is truly deserving of this honor.”
Wilkes received a bachelor of science degree from Villanova University and his medical degree from Temple University. He then completed his residency at Temple University Hospital, followed by a pulmonary and critical care fellowship at the University of Texas Southwestern Medical Center. He is also a military veteran, having served three years as a major in the U.S. Air Force Medical Corps.
Before coming to UVA, Wilkes worked at Indiana University for 22 years, rising to become executive associate dean for research affairs at the Indiana University School of Medicine. He also served as the university’s assistant vice president for research and as director of the Strategic Research Initiative for the Indiana University School of Medicine and Indiana University Health, as well as director of the Indiana University School of Medicine’s Physician Scientist Initiative.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the